Proteasome Inhibitor Carfilzomib Enhances the Anticancer Effect of Paclitaxel in MDA-MB-231 Breast Cancer Cells

Basit Öğe Kaydı
dc.contributor.authorTerzi, Hatice
dc.contributor.authorMustafa, E.
dc.contributor.authorErgul, Merve
dc.contributor.authorAhmet, A.
dc.contributor.authorMehmet, S.
dc.date.accessioned2024-10-26T18:02:16Z
dc.date.available2024-10-26T18:02:16Z
dc.date.issued2019
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstracty This study was aimed to determine the anticancer efficacy of the combination of paclitaxel, the standard treatment of breast cancer, and carfilzomib, which is a proteasome inhibitor, in breast cancer cells in vitro. Paclitaxel, carfilzomib and their combinations at various concentrations were added to MDA-MB-231 human breast cancer cells, and cell viability was detected using the XTT assay. Combination index values were determined using the Chou-Talalay method. Apoptotic effect and cell cycle arrest of single administrations and combinations of these agents were also evaluated using the flow cytometry. According to the results of the XTT assay, the combination produced a greater anticancer effect than that produced by both agents administered alone. Chou-Talalay approaches exhibited that the combination of paclitaxel and carfilzomib demonstrated a synergistic effect. The flow analysis showed that the combinations have induced a cell cycle arrest of MDA-MB-231 cells at G2/M phase and significantly induced apoptosis. The present study revealed that carfilzomib could significantly increase the efficacy of paclitaxel in human breast cancer cells in vitro. It is recommended that carfilzomib to be used along with paclitaxel in metastatic breast cancer patients to increase the anticancer effect and reduce potential toxicity-related side effects.
dc.identifier.doi10.36468/pharmaceutical-sciences.616
dc.identifier.endpage1153
dc.identifier.issn0250-474X
dc.identifier.issn1998-3743
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85082857871
dc.identifier.scopusqualityN/A
dc.identifier.startpage1146
dc.identifier.urihttps://doi.org/10.36468/pharmaceutical-sciences.616
dc.identifier.urihttps://hdl.handle.net/20.500.12418/28056
dc.identifier.volume81
dc.identifier.wosWOS:000508454900022
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherIndian Pharmaceutical Assoc
dc.relation.ispartofIndian Journal of Pharmaceutical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectApoptosis
dc.subjectbreast cancer
dc.subjectcarfilzomib
dc.subjectcell cycle
dc.subjectpaclitaxel
dc.titleProteasome Inhibitor Carfilzomib Enhances the Anticancer Effect of Paclitaxel in MDA-MB-231 Breast Cancer Cells
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu